DK1789044T3 - Phenylaminopyridiner og phenylaminopyraziner - Google Patents

Phenylaminopyridiner og phenylaminopyraziner

Info

Publication number
DK1789044T3
DK1789044T3 DK05787155.0T DK05787155T DK1789044T3 DK 1789044 T3 DK1789044 T3 DK 1789044T3 DK 05787155 T DK05787155 T DK 05787155T DK 1789044 T3 DK1789044 T3 DK 1789044T3
Authority
DK
Denmark
Prior art keywords
diseases
optionally substituted
phenylaminopyridines
phenylaminopyrazines
optionally
Prior art date
Application number
DK05787155.0T
Other languages
English (en)
Inventor
Subho Roy
Martin Eberle
Felix Bachmann
Alessandro Strebel
Goutam Saha
Godhuli Nandi
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Application granted granted Critical
Publication of DK1789044T3 publication Critical patent/DK1789044T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK05787155.0T 2004-09-06 2005-09-05 Phenylaminopyridiner og phenylaminopyraziner DK1789044T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405552 2004-09-06
PCT/EP2005/054371 WO2006027348A1 (en) 2004-09-06 2005-09-05 Phenylaminopyridines

Publications (1)

Publication Number Publication Date
DK1789044T3 true DK1789044T3 (da) 2010-12-06

Family

ID=34932262

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05787155.0T DK1789044T3 (da) 2004-09-06 2005-09-05 Phenylaminopyridiner og phenylaminopyraziner

Country Status (9)

Country Link
US (1) US8288421B2 (da)
EP (1) EP1789044B1 (da)
AT (1) ATE485822T1 (da)
CA (1) CA2578047C (da)
DE (1) DE602005024417D1 (da)
DK (1) DK1789044T3 (da)
ES (1) ES2352748T3 (da)
PL (1) PL1789044T3 (da)
WO (1) WO2006027348A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009107391A1 (ja) * 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
WO2012162818A1 (en) * 2011-06-03 2012-12-06 Queen's University At Kingston Substituted diarylamines and use of same as antioxidants
WO2013192088A1 (en) * 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9376418B2 (en) * 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2019100062A1 (en) 2017-11-20 2019-05-23 Ichan School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
ES3038913T3 (en) 2018-03-20 2025-10-15 Icahn School Med Mount Sinai Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes
US20230234935A1 (en) * 2020-06-26 2023-07-27 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1351691A4 (en) 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
WO2004087679A1 (en) * 2003-04-01 2004-10-14 Aponetics Ag 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
WO2005058876A1 (en) 2003-12-16 2005-06-30 Gpc Biotech Ag Pyrazine derivatives as effective compounds against infectious diseases
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines

Also Published As

Publication number Publication date
ATE485822T1 (de) 2010-11-15
US20080221171A1 (en) 2008-09-11
DE602005024417D1 (de) 2010-12-09
US8288421B2 (en) 2012-10-16
ES2352748T3 (es) 2011-02-22
EP1789044A1 (en) 2007-05-30
PL1789044T3 (pl) 2011-04-29
CA2578047C (en) 2011-04-19
EP1789044B1 (en) 2010-10-27
CA2578047A1 (en) 2006-03-16
WO2006027348A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
SE0202133D0 (sv) Novel compounds
DE60315492D1 (de) Medizinisch verwendbare arylethanolamin verbindungen
NO20050828L (no) lndol-3-svovelderivater
DE60318193D1 (en) Phenethanolaminderivate
HUP0401889A2 (hu) 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
BG106013A (en) New compounds and compositions as protease inhibitors
SE0202539D0 (sv) Compounds
DE60140814D1 (de) N-phenyl-2-pyrimidine-amine derivatives
HUP0303283A2 (hu) Új piridinilcsoporttal szubsztituált pirazolopiridin-származékok, előállításuk és alkalmazásuk szív- és keringési betegségek kezelésére alkalmas gyógyszerkészítmény előállítására
SE0104140D0 (sv) Novel Compounds
HRP20050688A2 (en) Pyrimidine derivatives for the prevention of hiv infection
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
HRP20050830A2 (en) Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases
SE0403171D0 (sv) New compounds
NO20045452L (no) Anvendelse av substituerte cyanopyrrolidiner og kombinasjonspreparater inneholdende disse for behandling av hyperlipidemi og assosierte sykdommer
SE0302139D0 (sv) Novel compounds
ATE402166T1 (de) Substituierte-1-phthalazinamine als vr-1- antagonisten
ZA202306437B (en) Salt and crystal form of nitrogen-containing heterocyclic derivative, preparation method therefor and application thereof
ATE482933T1 (de) Sulfopyrrolderivate